Arca
Skip to content

Venous thrombosis

Drug research and approvals for venous thrombosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 194 studies of venous thrombosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 194
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 194 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 25, 2026Open-label, multi-center, single-dose phase 1 study to investigate the pharmacokinetics, safety, and tolerability of milvexian in pediatric patients from 28…MILVEXIAN (BMS-986177, JNJ-70033093)Johnson & JohnsonPending
May 2, 2024A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of bay 3018250 in patients with symptomatic proximal deep…BAY 3018250BayerClosed
Dec 24, 2020A randomized controlled trial on the use of postoperative extended venous thromboprophylaxis in patients with inflammatory bowel disease. a pilot studyAPIXABANMCMASTER UNIVERSITYOngoing
Sep 18, 2018Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. a pilot, prospective cohort study.RIVAROXABANOTTAWA HOSPITAL RESEARCH INSTITUTEClosed
Apr 20, 2018Perioperative ischemic evaluation-3 (poise-3) trialTRANEXAMIC ACIDHAMILTON HEALTH SCIENCES CORPORATIONClosed
Dec 18, 20157-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months…XARELTO (RIVAROXABAN, BAY 59-7939)BayerClosed
Oct 2, 201530-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in…XARELTO (RIVAROXABAN, BAY 59-7939)BayerClosed

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Mar 30, 2007CeprotinPrevention and treatment of venous thrombosis and purpura fulminansBaxalta US, Inc.Approved

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Mar 20, 2002Arixtrafondaparinux sodiumViatris Healthcare LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.